Biotechnology Sector

In the wake of escalating global water management challenges, the necessity for advanced monitoring technologies within critical infrastructure has never been more urgent. A pioneering study published recently in Communications Engineering unravels a sophisticated method for real-time monitoring of water states in large-diameter aqueducts using distributed acoustic sensing (DAS) signals. This breakthrough technology promises to

In a groundbreaking development poised to revolutionize the treatment of liver injuries, scientists have engineered biosilica nanoparticulate scavengers to combat hepatic ischemia–reperfusion injury (IRI), a pervasive clinical challenge that significantly complicates liver surgeries and transplantation outcomes. This innovative nanomedicine strategy targets the oxidative stress and inflammatory cascades lying at the heart of ischemia–reperfusion injury, offering

In the evolving landscape of cancer survivorship, psychological well-being remains a critical yet often underexplored dimension of recovery. A groundbreaking study recently published in BMC Cancer probes the intricate relationship between loneliness and depression among cancer survivors, with a particular focus on adolescents and young adults (AYAs). This research sheds light on the unprecedented mental

In a groundbreaking development that challenges existing paradigms in immunotherapy, new research reveals an intricate crosstalk between regulatory T cells (Tregs) and pro-inflammatory T helper 17 (Th17) cells mediated through a delicate balance of cytokines, primarily TGF-β, IL-6, and IL-2. This study, spearheaded by Cheng, Nan, Ji, and colleagues, unfolds a paradoxical mechanism whereby Treg

In the relentless pursuit of more effective treatments for advanced biliary tract cancer (ABTC), a recent multicentre, randomized phase II clinical trial has unveiled promising insights into chemotherapy regimens that could alter the therapeutic landscape. Published in BMC Cancer, this study rigorously compared the efficacy and safety profiles of nab-paclitaxel combined with cisplatin versus the

The silent origins of cardiometabolic disease have long puzzled the medical community, prompting scientists to look back to the earliest stages of human life for answers. A groundbreaking study published recently in Pediatric Research brings new insights into how metabolic markers present at birth could foreshadow the development of cardiometabolic risk factors in adolescence. This

In a groundbreaking clinical inquiry poised to reshape neonatal intensive care, researchers are probing the therapeutic promise of combining budesonide, a potent corticosteroid, with surfactant delivered intratracheally to extremely preterm infants. This innovative approach targets bronchopulmonary dysplasia (BPD), a chronic lung disease that afflicts the most vulnerable neonates, threatening long-term respiratory health and survival. The

In a groundbreaking comparative study published in the 2025 issue of BMC Cancer, researchers from the Fourth Hospital of Hebei Medical University have revealed compelling evidence that chemoimmunotherapy may revolutionize the treatment landscape for patients suffering from locally advanced esophageal squamous cell carcinoma (LAESCC). This large-scale retrospective cohort study meticulously compared the survival outcomes of

In the rapidly evolving field of oncology, one of the most perplexing challenges remains the management of cancer of unknown primary (CUP). This enigmatic diagnosis occurs when metastatic cancer is detected, but despite exhaustive investigations, the site of origin cannot be identified. Patients with CUP historically face a grim prognosis due to limited treatment options

In recent years, the intricate relationship between the human gut microbiota and colorectal cancer has captivated the scientific community, revealing profound interdependencies that extend far beyond simple microbial colonization. A groundbreaking study led by Tang, Li, and colleagues has now shed new light on an overlooked factor that may significantly influence colorectal tumorigenesis: cholecystectomy, or

In the ever-evolving world of neonatal care, the management of respiratory distress in extremely low birth weight (ELBW) infants remains a critical challenge. Recent advances have introduced cutting-edge technologies that promise to revolutionize the way clinicians approach ventilatory support in these vulnerable patients. A groundbreaking study, led by Kato et al., delves into the perspectives

In a groundbreaking and comprehensive study recently published in BMC Cancer, researchers Liu and Han have shed new light on the evolving landscape of lip and oral cavity cancer (LOCC) among individuals aged 60 and above, spanning over three decades from 1990 to 2021. Utilizing the expansive 2021 Global Burden of Disease (GBD) database, their

A revolutionary multi-institutional initiative spearheaded by researchers at Weill Cornell Medicine has secured an ambitious five-year, $14.9 million grant from the National Institute of Allergy and Infectious Diseases, a division of the National Institutes of Health. This funding will empower scientists to develop innovative strategies designed to eradicate latent HIV within infected individuals. Distinguished by

In the continuously evolving field of oncological pharmacotherapy, mitigating adverse drug reactions remains a pivotal challenge. Recent research published in BMC Cancer presents compelling evidence on the effectiveness of dexamethasone, a corticosteroid extensively used to prevent hypersensitivity reactions (HSRs) during chemotherapy. The randomized controlled trial examined the non-inferiority of a lower 10 mg dose of

Recent advancements in solid-state ionics have brought to light the intricate mechanisms governing ion transport in lithium-ion conductors. The study conducted by Aydi, Dardouri, Znaidia, and their team delves deep into the realm of LISICON (Lithium Superionic Conductor) structures. By employing dielectric spectroscopy alongside electrothermal modeling, the researchers sought to unravel the complexities inherent in

A groundbreaking meta-analysis conducted by an international team of psychologists has unveiled a significant connection between environmental sensitivity and the prevalence of common mental health disorders, including depression and anxiety. This comprehensive synthesis of 33 studies, the first meta-analytic investigation of its kind, illuminates the nuanced ways in which highly sensitive individuals process external stimuli

In the evolving landscape of advanced manufacturing, the fusion of ceramics with additive manufacturing technologies has emerged as a frontier rich with potential. One recent study, conducted by Cramer et al., delivers significant advancement in the rheological optimization of silicon nitride and resin slurries engineered explicitly for vat photopolymerization printing followed by sintering. This development

Mount Sinai Marks 13th Year as Official Medical Provider at the US Open, Elevating Sports Medicine Through Advanced Onsite Care New York’s Mount Sinai Health System proudly continues its long-standing partnership as the official hospital and medical services provider for the US Open Tennis Championships, entering its 13th consecutive year in this prestigious role in

Over the last two decades, CD40 agonist antibodies have emerged as a beacon of hope in cancer immunotherapy, promising to marshal the immune system’s power against malignancies. Despite impressive results in preclinical animal models, their translation to human therapy has been fraught with challenges. Systemic toxicity, including severe inflammatory responses, thrombocytopenia, and hepatotoxicity, severely limited

America’s mental health crisis among youth has escalated to alarming levels, with new research revealing a troubling pattern of extended stays for children in hospital emergency departments. According to the latest study conducted by Oregon Health & Science University (OHSU), a significant number of young patients suffering primarily from suicide-related behaviors and depression are forced

About a week ago, on August 8th, fell International Cat Day. Even if you are a cat person like I am, you might have missed the event. Don’t worry, your feline probably didn’t know about it either. In this article, we will take a look at what biotech is doing in cat health. While the cat The post How biotech is improving the life of your cat  appeared first on Labiotech.eu. © Labiotech UG and Labiotech.eu. Unauthorized use and/or duplication of this material without express and written permission from this site’s author and/or owner is strictly prohibited. Excerpts and links may be used, provided that full and clear credit is given to Labiotech UG and Labiotech.eu with appropriate and specific direction to the original content.

This week's guest is Cosmo Feilding of Beckley PsyTech, a UK biotech working with next generation psychedelics that could redefine depression treatment. The post Are next-generation psychedelics the way forward for addressing treatment resistant depression? appeared first on Labiotech.eu. © Labiotech UG and Labiotech.eu. Unauthorized use and/or duplication of this material without express and written permission from this site’s author and/or owner is strictly prohibited. Excerpts and links may be used, provided that full and clear credit is given to Labiotech UG and Labiotech.eu with appropriate and specific direction to the original content.

Omeros’ efforts to get its transplant drug to market have already suffered one FDA rejection. Now, the biotech’s second shot at approval has been pushed back by three months.

Experienced business developer Derek Hicks has been handed the reins of Rezo Therapeutics, his first time at the helm of a biotech. Hicks most recently was chief business officer at Intellia Therapeutics and before that served a yearlong stint as head of business development at Spark Therapeutics.

Evotec previously planned to lay off 400 staffers amid a sweeping reorganization. It has actually cut roughly 600 as of June.

Prelude Therapeutics’ lead asset won’t be making it to the second act. The precision oncology outfit is pausing development of SMARCA2 degrader PRT3789, leaving just one clinical program left humming in its pipeline.

Having backed Superluminal Medicines’ series A last year, Eli Lilly has now signed a $1.3 billion pact with the G protein-coupled receptor biotech.

Schrödinger is abandoning its CDC7 inhibitor after the therapy was linked to the deaths of two patients in a phase 1 leukemia trial.

A patient has died from kidney injury in a trial of CytomX Therapeutics’ lead antibody-drug conjugate, although the biotech has been advised to stick with the study.

Sarepta Therapeutics is selling off Arrowhead Pharmaceuticals shares to stretch its cash runway while also inking a share transfer to pay off half of a $100 million payment owed to the latter.

Vedanta Biosciences’ dreams of using live bacteria to treat inflammatory bowel disease have been dashed. The Massachusetts-based microbiome outfit’s mixture of 16 bacterial strains failed to reduce disease severity in the colons of patients with ulcerative colitis, Vedanta said Wednesday.

Discover how melanoma vaccines are gaining traction in the clinic and could soon become a treatment option for this deadly skin cancer. The post Injecting hope into skin cancer treatment: The promise of melanoma vaccines appeared first on Labiotech.eu. © Labiotech UG and Labiotech.eu. Unauthorized use and/or duplication of this material without express and written permission from this site’s author and/or owner is strictly prohibited. Excerpts and links may be used, provided that full and clear credit is given to Labiotech UG and Labiotech.eu with appropriate and specific direction to the original content.

Hatteras Venture Partners has secured over $200 million across a pair of funds that are set to benefit up-and-coming biotechs alongside medtech and healthtech companies.

Response Pharmaceuticals has shared phase 2 data in post-GLP-1 patients, linking its ex-Sanofi asset to reductions in blood-fat levels and weight gain in previous users of obesity drugs.

Oric’s previously announced plan to focus resources come with a sting in its tail—the therapeutic resistance-focused biotech is laying off 20% of its employees to finance the strategy.

Generation Bio is shedding 90% of its workforce after the biotech acknowledged that it’s unlikely to find the cash to take its lipid nanoparticle tech into the clinic.

More bad news has come down for Biohaven’s small molecule troriluzole. After the FDA decided to convene an advisory committee to consider the asset’s potential approval in a rare disease, pushing the PDUFA date to the fourth quarter, troriluzole has now failed a phase 3 trial in obsessive-compulsive disorder.

The director of the National Institutes of Health has attributed the federal government’s discontinuation of mRNA vaccine development to a lack of public trust that has made the platform “no longer viable."

Discover six of the top psychedelic companies developing novel drugs to expand the treatment scope for mental health indications. The post Six psychedelic drug companies aiming to revolutionize mental health treatment appeared first on Labiotech.eu. © Labiotech UG and Labiotech.eu. Unauthorized use and/or duplication of this material without express and written permission from this site’s author and/or owner is strictly prohibited. Excerpts and links may be used, provided that full and clear credit is given to Labiotech UG and Labiotech.eu with appropriate and specific direction to the original content.

After HHS abruptly canceled about $500 million in funding for mRNA vaccine development, one senior agency leader has decided to call it quits. Alastair Thomson is resigning as chief data officer at the Advanced Research Projects Agency for Health, he announced in a LinkedIn post that has since been deleted.

Using its hub-and-spoke business model, PureTech is launching a new subsidiary, Celea Therapeutics, to develop its promising candidate for idiopathic pulmonary fibrosis (IPF) and other fibrotic and inflammatory lung conditions.

Bayer has teamed up with Kumquat Biosciences for a juicy opportunity, committing up to $1.3 billion for the global license to a KRAS G12D inhibitor that is on the cusp of the clinic.

A day after posting a pair of phase 3 wins for the tricky indication of Sjögren's syndrome, the Swiss pharma has unveiled a separate late-stage victory in another B-cell-driven autoimmune disease.

Vaxart is actively seeking more information about why it was told to stop work under a federally funded COVID-19 vaccine contract.

Another Massachusetts biotech has reached the end of the road. NextRNA Therapeutics has begun winding down operations with a “heavy heart,” the company’s co-founder, president and CEO Dominique Verhelle, Ph.D., announced in an Aug. 9 LinkedIn post.

Zombie biotechs continue to exist despite setbacks. Some players in the industry want to free the capital and eliminate these companies. The post Zombie biotechs and the mission to make them disappear fast appeared first on Labiotech.eu. © Labiotech UG and Labiotech.eu. Unauthorized use and/or duplication of this material without express and written permission from this site’s author and/or owner is strictly prohibited. Excerpts and links may be used, provided that full and clear credit is given to Labiotech UG and Labiotech.eu with appropriate and specific direction to the original content.

Young inflammatory disease biotech Expedition Therapeutics is paying $17 million cash for licensing rights to an investigational DPP-1 inhibitor from Fosun Pharma.

IO Biotech’s cancer vaccine has “narrowly” failed to beat Keytruda in a phase 3 melanoma trial, but the company remains hopeful of a path to approval.

Novartis may have abandoned one of its Sjögren's syndrome assets this year, but it now looks like the pharma has a winner on its hands.

Learn about July 2025’s top biotech deals, featuring major collaborations in small molecules, antibodies, and drug delivery. The post Top biotech deals in July 2025  appeared first on Labiotech.eu. © Labiotech UG and Labiotech.eu. Unauthorized use and/or duplication of this material without express and written permission from this site’s author and/or owner is strictly prohibited. Excerpts and links may be used, provided that full and clear credit is given to Labiotech UG and Labiotech.eu with appropriate and specific direction to the original content.

Recently the UK government announced plans to sequence the DNA of every baby born in that country. Why, how, and what will it cost? The post Day One DNA: How and why the UK is betting on whole genome sequencing for every newborn appeared first on Labiotech.eu. © Labiotech UG and Labiotech.eu. Unauthorized use and/or duplication of this material without express and written permission from this site’s author and/or owner is strictly prohibited. Excerpts and links may be used, provided that full and clear credit is given to Labiotech UG and Labiotech.eu with appropriate and specific direction to the original content.

Fusion proteins have drawn investors these past months attracting dollars from deep pockets in the pursuit of commercial success.  The post Fusion proteins attract funds and biopharma partnerships  appeared first on Labiotech.eu. © Labiotech UG and Labiotech.eu. Unauthorized use and/or duplication of this material without express and written permission from this site’s author and/or owner is strictly prohibited. Excerpts and links may be used, provided that full and clear credit is given to Labiotech UG and Labiotech.eu with appropriate and specific direction to the original content.

Discover 10 key oncology deals that have been made so far in 2025, spotlighting where industry leaders are betting big. The post 10 oncology deals in 2025 spotlight where industry leaders are betting big appeared first on Labiotech.eu. © Labiotech UG and Labiotech.eu. Unauthorized use and/or duplication of this material without express and written permission from this site’s author and/or owner is strictly prohibited. Excerpts and links may be used, provided that full and clear credit is given to Labiotech UG and Labiotech.eu with appropriate and specific direction to the original content.

Abivax, MapLight Therapeutics, Everest Medicines, and Soleno Therapeutics bagged the biggest biotech funding rounds overall in July 2025. The post The biggest biotech funding rounds in July 2025 appeared first on Labiotech.eu. © Labiotech UG and Labiotech.eu. Unauthorized use and/or duplication of this material without express and written permission from this site’s author and/or owner is strictly prohibited. Excerpts and links may be used, provided that full and clear credit is given to Labiotech UG and Labiotech.eu with appropriate and specific direction to the original content.

This past year has seen various developments in the field of oncolytic virus therapies - in fundraising and in the clinic. The post Oncolytic virus therapy for cancer: what’s been going on in 2025?  appeared first on Labiotech.eu. © Labiotech UG and Labiotech.eu. Unauthorized use and/or duplication of this material without express and written permission from this site’s author and/or owner is strictly prohibited. Excerpts and links may be used, provided that full and clear credit is given to Labiotech UG and Labiotech.eu with appropriate and specific direction to the original content.

Is cultivated meat the future of pet food? Meatly's CEO shares how lab-grown meat is changing pet diets—and possibly human ones too. The post Meatly’s innovative cultivated meat is already delighting pets, are humans next? appeared first on Labiotech.eu. © Labiotech UG and Labiotech.eu. Unauthorized use and/or duplication of this material without express and written permission from this site’s author and/or owner is strictly prohibited. Excerpts and links may be used, provided that full and clear credit is given to Labiotech UG and Labiotech.eu with appropriate and specific direction to the original content.

Navigating the Complex World of Global Drug Patents: Strategies and Challenges Ahead As a pharmaceutical professional, you know how crucial it is to protect your innovative drug patents in the global market. With the rise of international trade and the... Source

The Complex World of Biologic Drugs: Navigating Patent Applications As a biotech professional, you're likely no stranger to the intricacies of developing life-saving treatments. But when it comes to biologic drugs, the process can be particularly chall... Source

Unlocking the Power of Combination Therapies: Strategies for Successful Patenting As a pharmaceutical professional, you know that combination therapies have revolutionized the treatment of complex diseases. By pairing two or more active ingredients, yo... Source

The Secret to Setting the Right Price for Your Generic Medications As a generic drug manufacturer, you're constantly looking for ways to stay ahead of the competition and bring affordable medications to market. But have you ever wondered how to set the... Source

Unlocking Efficiency in the Generic Drug Supply Chain As the pharmaceutical industry continues to evolve, the generic drug supply chain has become a critical component of ensuring timely and affordable access to life-saving medications. However, naviga... Source

Breaking News: FDA Updates - What Do the Latest Changes Mean for Generic Drug Approval? As a healthcare professional or a business leader in the pharmaceutical industry, you're likely aware of the complex landscape surrounding generic drug approval. Re... Source

Breaking Down Barriers: Navigating Regulatory Challenges in Latin America's Generic Drug Market As the demand for affordable generic medications continues to grow, Latin America has emerged as a critical region for pharmaceutical companies looking to e... Source

The Future of Affordable Healthcare: Can Biosimilars Deliver? As healthcare professionals, we're constantly on the lookout for innovative solutions to improve patient outcomes while reducing costs. One promising approach is the use of biosimilars – bio... Source

Ensuring the Highest Quality in Generic Medications: A Crucial Step in Healthcare As the global demand for affordable healthcare continues to rise, generic medications have become a vital lifeline for millions of people worldwide. However, with the inc... Source

The Unseen Heroes of Generic Medicines: The Crucial Role of Quality Assurance As we navigate the complex world of pharmaceuticals, it's easy to overlook the unsung heroes behind the scenes. But today, I want to shine a spotlight on the Quality Assuranc... Source

Can Lurbinectedin Treat Ovarian Cancer? A Comprehensive Review Ovarian cancer is a devastating disease that affects thousands... https://www.Drugchatter.com/chat/25460/can-lurbinectedin-treat-ovarian-cancer/ Source

Unlocking the Potential of Biosimilars: Navigating Regulatory Considerations for Clinical Efficacy Trials As the pharmaceutical industry continues to evolve, biosimilars have emerged as a game-changer in the quest for affordable and accessible treatmen... Source

Unlock the Secrets of Drug Patent Searching: A Beginner's Guide As a professional in the pharmaceutical industry, staying ahead of the curve is crucial. One of the most critical aspects of this is understanding the world of drug patents. But have you e... Source

Unlocking the Path to Generic Medication Approval: A Step-by-Step Guide As a healthcare professional or a business leader in the pharmaceutical industry, you're likely aware of the complex landscape surrounding generic medication approval. With the eve... Source

The Future of Biosimilars: Switching Strategies for Success As the biosimilar market continues to grow, one question on everyone's mind is: how can we make the most of this opportunity? One strategy that's gaining traction is biosimilar-to-biosimilar s... Source

The Hidden Factors Behind FDA-Approved Drugs' Patent Challenges As a healthcare professional or a pharmaceutical industry expert, you're likely no stranger to the complex world of drug patents. But have you ever wondered what sets some FDA-approved dru... Source

Breaking Down Barriers: The Power of Partnerships in Generic Drug Development As the pharmaceutical industry continues to evolve, one thing is clear: collaboration is key. In the world of generic drug development, partnerships are playing an increasing... Source

Does Fish Oil Interact with Vascepa? A Comprehensive Guide As the world becomes increasingly aware of the importance of... https://www.Drugchatter.com/chat/45752/does-fish-oil-interact-with-vascepa/ Source

The Art of Timing: Mastering Generic Drug Development Timelines As a seasoned professional in the pharmaceutical industry, you know that navigating the complex landscape of generic drug development can be a daunting task. One of the most critical facto... Source

The Impact of Lipitor on White Wine: A Comprehensive Guide As a popular cholesterol-lowering medication, Lipitor (atorvastatin)... https://www.Drugchatter.com/chat/37341/how-does-lipitor-affect-white-wine/ Source

As always, if you know of layoffs occurring at a biotech, please reach out to the Fierce Biotech editorial team.